Responses
Scientific Abstracts
Late Breaking Abstracts
Late Breaking Abstract Session
LB0003 Tocilizumab (TCZ) monotherapy is superior to adalimumab (ADA) monotherapy in reducing disease activity in patients with rheumatoid arthritis (RA): 24-week data from the phase 4 adacta trial
Compose a Response to This Article
Other responses
No responses have been published for this article.